Merck, Keytruda and Halozyme
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret antigens that could form the backbone of off-the-shelf immunotherapies.
Zacks Investment Research on MSN6d
Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and ...
Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...
We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...
Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...
While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...
It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback